Clinical Guide to   
Probiotic Products   
       Available in Canada: 15th Edition
 Dosage Formats | Applications | Clinical Evidence  to date
2023Table of Contents
Page Number Content
2 Acronyms for Potential Applications of Probiotics in the Adult 
and Pediatric Population
3 About this Guide
4 Review Process
5 Inclusion Criteria
6 Level of Recommendation and Disclaimer
7 Probiotic Products for Digestive  and Liver Health in Adult 
Population
10 Probiotic Products for General Health in Adult Population
11 Probiotic Products for Pediatric Population
14 Probiotic Products for Maternal and Vaginal Health
15 Functional Foods  with Added Probiotics
16 References
22 Alliance for Education on Probiotics
   ISBN: 978-1-7775181-3-41
Author
Dragana Skokovic-Sunjic
BScPhm RPh NCMP
Reviewers
Dr Vivien Brown
MDCM CCFP FCFP NCMP
Iris Krawchenko
BScPhm RPh ACPR
Dr Ruben Hummelen
MD MSc PhD CCFP
Dr John Marshall
MD MSc FRCPC AGAF
Dr Tom Smiley
BScPhm PharmD
Editor
Rebecca L. Johnson
PhD candidateAcronyms:
AAD Antibiotic associated diarrhea - Prevention ID Infectious diarrhea
BV Bacterial vaginosis LDL-C Reduces LDL and total cholesterol
C Constipation LH Liver Health (NASH/NAFLD/MHE; as adjunct to 
standard therapy; see studies for specific population)
CDAD Clostridium difficile associated diarrhea - Prevention M/A Mood and Affect (symptoms related to stress/anxiety; 
not a substitute for standard treatment)
CE/AD Childhood eczema/ Atopic dermatitis Mastitis Mastitis in breastfeeding mothers  (treatment and 
prevention)
CID Common infectious disease - community acquired NEC* Necrotizing Enterocolitis (newborn) *as per hospital 
protocol, not for self-administration
CMPA Cow Milk Protein Allergy (including Colic due to CMPA) NI Nosocomial infections prevention - hospital acquired
Colic Colic OH Oral health (reductions of tonsillitis, laryngitis, and 
dental caries)
FAP Functional abdominal pain Regurg/ 
GI MotReduces regurgitation/ Improves gastrointestinal 
motility
HP Helicobacter pylori - Adjunct to standard eradication 
therapyTD Travelerâ€™s diarrhea prevention
IBD-P Inflammatory bowel disease - Pouchitis VC Vulvovaginal candidiasis
IBD-UC IBD - Ulcerative colitis - Adjunct to standard therapy WM Weight Management (aids in reduction of body weight, 
body fat mass, and waist circumference)
IBS Irritable bowel syndrome2The Clinical Guide to Probiotic Products Available in Canada
This Guide is a practice tool to assist with clinical decision-making for appropriate 
probiotic therapy for your patients. 
It is designed to translate scientific evidence available for probiotic products to 
practical, clinically relevant information. It is intended to be used as a clinical decision-
making tool, enabling clinicians to easily select the appropriate product, dose, and 
formulation for a specific indication.
Our aim is to ensure that the appropriate product/strain is selected for the desired 
outcome. This Clinical Guide is not meant to be interpreted as a systematic review, or 
a â€œclinical practice guideline,â€ nor is it an endorsement for companies to market health 
claims.
Currently, the body of evidence for probiotic interventions is growing along with 
popular demand for these products. There is evidence to support the use of probiotic 
products for a variety of indications beyond gut health, however, applications and results 
are strain-specific.
Due to frequent changes in the commercial availability of probiotic strains, new 
published evidence, and growing research, an annual review and updates of this Clinical 
Guide have been conducted since 2008. A general lack of adverse effects attributable to 
probiotics supports the widespread use of these products, but an ongoing investigation 
is recommended.3How is the Guide Reviewed?
A systematic literature review using pre-defined inclusion criteria was undertaken to 
identify studies of defined clinical outcomes for specific probiotic strain(s). Commercially 
available products containing said strain(s) were identified, and the levels of evidence 
were used to rate the strength of the expected benefit. This information was compiled 
into a chart format. Data was assessed by a group of independent expert reviewers. 
In the case of probiotics, the clinical evidence must be linked to specific formulations 
as defined by genus, species, alphanumeric designation or strain, number of live 
bacteria present, the blend of probiotic strains present, and finally, non-active 
ingredients present. 
Every attempt was made to include the published clinical data for the available 
probiotic formulations. 
To avoid selection bias toward any specific formulation, we have conducted a literature 
search of two databases (PubMed, EMBASE) and contacted our independent experts to 
identify any published or unpublished studies.4Why are only a Limited Number of Products Included?
All of the inclusion criteria listed must be satisfied for a product to be listed in the Guide: 
1.  Commercially available in Canada as a supplement or probiotic-containing food. 
2.  Generally Recognized as Safe status (FDA) and/or Natural Product Number   
  (Health Canada) for probiotic strain(s) used in the products. 
3.  Favourable published clinical evidence for the particular strain(s) present in each   
  product. 
4.  For products containing multiple strains, evidence must be for the specified   
  combination and NOT extrapolated from the evidence for the separate probiotic 
  strains.
Note:  Some products are excluded from the current edition due to changes in the strains used.  
Clinical Pear l: Indications for use are based on specific strains or combinations studied together.  
Caution: Extrapolation of current data and recommendations to be applied for different combinations 
of probiotic strains is not permitted.5Level of Recommendation:  
 
Level I Evidence obtained from at least one appropriately designed trial (e.g. randomization, blinding, appropriate population 
comparisons) with a power calculation for the outcome(s) of interest.  
The expert review board reserves the right to make the final decision for the level of recommendation. (HIGHEST LEVEL)
Level II Evidence obtained from well-designed controlled trials without randomization; evidence obtained from randomized trials not 
satisfying all criteria listed in Level I. Evidence obtained from well-designed cohort or case-control analytic studies, preferably 
from more than one center or research group.  
Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be 
regarded as this type of evidence.
Level III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. 
 
Readers are strongly encouraged to review the evidence listed for each product for themselves.  
Please refer to individual publications for specifics of patient populations studied (e.g. age, gender, comorbidities) and details of 
clinical effect (statistical significance, size of treatment effect, precision of the confidence intervals).6
Disclaimer
 
The statements made regarding products listed here have not been evaluated by the Food and Drug Administration or Health Canada (unless otherwise indicated). These 
products are not intended to diagnose, treat, cure or prevent any disease. Products, services, information and other content provided in this Guide, including information that 
may be provided in this Guide directly or by linking to third-party affiliates are provided for informational purposes only. Please consult with a physician or another healthcare 
professional regarding any medical or health-related questions. Manufacturer indications for use can be found on product labels. This chart is reflective of published evidence 
available to date. It does not represent an endorsement of any specific product. Work on this Guide is done independently and without financial conflict. In order to minimize 
bias, publishing and distribution efforts are coordinated via Alliance for Education on Probiotics (AEProbio). We are grateful for the unrestricted publishing grant AEProbio is 
providing for continuous efforts to translate science into a clinically applicable form.
Please forward any questions or comments to DSunjic@bhsoftinc.com
2023 Version, valid until December 31, 2023. Â©BHSoftIncProbiotic Products for  Digestive and Liver Health in Adult Population:
Brand Name Probiotic Strain(s) Dosage 
FormCFU/dose No. of 
doses/day
C
HP
CDAD
IBS
ID
AAD
IBD-P
TD
AlignÂ® ğŸŒ¾
B. longum  35624Capsule 1B/capsule 1 capsuleI ğŸ 
(1-4)AlignÂ® Chewables ğŸŒ¾ Tablet 1B/tablet 1 tablet
Bio-K+Â® Antibio Pro ğŸŒ¾ 
Shelf stable and refrigerated options 
available
L. acidophilus  CL1285  
L. casei  LBC80R  
L. rhamnosus  CLR2Capsule 50B/capsule 1-2 capsules
I ğŸ 
(6-10)I ğŸ 
(5-7)Bio-K+Â® BiomePRO 
Drinkable Probiotic ğŸŒ¾â„Ferm. rice lq. 100B/bottle 0.5-1 bottle
Bio-K+Â® Drinkable 
Probiotics ğŸŒ¾â„Ferm. milk lq.  
Ferm. vegan lq.50B/bottle  
50B/bottle1 bottle  
1 bottle
Bio-K+Â® IBS Pro ğŸŒ¾ 
Shelf stable and refrigerated options 
availableL. acidophilus  CL1285  
L. casei  LBC80R  
L. rhamnosus  CLR2Capsule 50B/capsule 2 capsulesI ğŸ 
(18)
BioGaiaÂ® ProtectisÂ® Baby 
Drops ğŸŒ¾
L. reuteri  DSM 17938Drops 100M/5 drops 5 drops
I ğŸ 
(17)I  
(13-16)II  
(11)II  
(12)BioGaiaÂ® ProtectisÂ® 
Chewable Tablets ğŸŒ¾Chewable 
tablet100M/tablet 1 tablet
BioGaiaÂ® ProtectisÂ® Drops 
with Vitamin D Drops 100M/5 drops 5 drops
BioGaiaÂ® Junior Tablets 
with Vitamin D ğŸŒ¾Chewable 
tablet100M/tablet 1 tablet
Biomed Bacillus CoagulansBacillus coagulans  MTCC 5856 Capsule 1B/capsule 2 capsulesII ğŸ 
(19)
CulturelleÂ® Digestive Daily 
Probiotic Chewables ğŸŒ¾
L. rhamnosus  GGChewable 
tablet10B/tablet 1 tablet
I  
(24)III  
(25-
27)I ğŸ 
(23)II  
(28)II ğŸ 
(29-30)CulturelleÂ® Digestive Health 
Daily Probiotic Capsules ğŸŒ¾Capsule 10B/capsule 1 capsule
â„- Product requires refrigeration  
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free7
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Digestive and Liver Health in Adult Population:
Brand Name Probiotic Strain(s) Dosage 
FormCFU/dose No. of 
doses/day
IBD-
UC
HP
CDAD
IBS
AAD
TD
Digestive Careâ„¢ 10 Billion 
Daily ProbioticL. plantarum  299v Capsule 10B/capsule 1-2 capsulesIII  
(32,36)I ğŸ 
(33-35)III  
(31)
FlorastorMaxÂ® ğŸŒ¾
Saccharomyces boulardii lyo  
CNCM I-745Sachet 10B/sachet 1 sachet
III  
(43,47-50)I ğŸ 
(44-46)I ğŸ 
(8-9,38-
39,51)I ğŸ 
(37-38)I ğŸ 
(40-42)FlorastorÂ® ğŸŒ¾ Capsule  
Sachet5B/capsule  
5B/sachet1-2 capsules  
1-2 sachetsHMF Forte ğŸŒ¾
L. acidophilus  CUL-60  
L. acidophilus  CUL-21  
B. animalis subsp. lactis  CUL-34  
B. bifidum  CUL-20Capsule 10B/capsule 2-3 capsules
II  
(52)II ğŸ 
(53)IBS Relief ğŸŒ¾ Capsule 25B/capsule 1 capsule
Intensive ğŸŒ¾ Capsule 25B/capsule 1 capsule
Intensive 50 ğŸŒ¾ Capsule 50B/capsule 1 capsule
Intensive Powder ğŸŒ¾â„Powder25B/1 scoop
(1 gram)1 scoop
Super Powder ğŸŒ¾â„Powder10B/1 scoop
(1 gram)2-3 scoops
MutaflorÂ® â„ Echerichia coli Nissle  1917 Capsule2.5-25B/
capsule1-2 capsulesI  
(57-60)
Pregnancy Care Probiotic ğŸŒ¾ L. rhamnosus  R0011  
L. helveticus  R0052Capsule 2B/capsule 1-2 capsulesIII  
(69)
Probiotic 10 Billion Active 
Cells Daily MaintenanceLactococcus lactis  (UALI-08)  
L. gasseri  (UALg-05)  
L. rhamnosus  (UALr-06)  
B. animalis subsp. lactis  (UABIa-12)  
B. breve (UABbr-11)  
L. paracasei (UALpc-04)  
L. rhamnosus  (UALr-18)  
L. acidophilus  (DDSÂ©-1)  
L. plantarum  (UALp-05)  
B. longum  subsp. longum (UABI-14)  
B. bifidum  (UABb-10)  
L. casei  (UALc-03)  
L. reuteri  (UALre-16)  
B. longum  subsp. infantis (UABi-13)Capsule 10B/capsule 3 capsulesII  
(68)
â„- Product requires refrigeration
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free8
www.ProbioticChart.ca
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Digestive and Liver Health in Adult Population:
Brand Name Probiotic Strain(s) Dosage 
FormCFU/dose No. of 
doses/day
C
IBD-
UC
CDAD
IBS
AAD
IBD-P
LH
Purica Probiotic Intensive 
GI ğŸŒ¾L. plantaru m CECT7484/
KABP022Â®  
L. plantaru m CECT7485/
KABP023Â®  
P. acidilactici CECT7483/
KABP021Â®Capsule 3B/capsule 1 capsuleI ğŸ 
(73-74)
Ultra Probiotic Complex by 
GNC ğŸŒ¾L. acidophilus  CUL-60  
L. acidophilus  CUL-21  
B. bifidum  CUL-20  
B. lactis CUL-34Packet  
Capsule25B/packet  
25B/ 50B/ 75B 
per capsule1-2 packets  
1-2 capsulesII  
(52)II  
(53)
UltraFloraÂ® Balance L. acidophilus  NCFMÂ®  
B. lactis Bi-07Â®Capsule 15B/capsule 2 capsulesII  
(78)
UltraFloraÂ® Intensive Care ğŸŒ¾L. plantarum  299v Capsule 10B/capsule 2 capsulesIII  
(32,36)I ğŸ 
(33-35)III  
(31)
UltraFloraÂ® Restore ğŸŒ¾ B. lactis Bi-07Â®  
L. acidophilus  NCFMÂ®  
B. lactis Bl-04  
L. paracasei Lpc-37Capsule 20B/capsule 1 capsuleI  
(75-76)
VisbiomeÂ® ğŸŒ¾â„ 
 
 
 
 
 
 
 
 
 
 
This combination of strains is 
known as De Simone Formulation 
and is the same one listed in 
references that cite VSL#3 as 
treatment regimenL. acidophilus  DSM24735/
SD5212  
L. paracasei DSM24733/
SD5218  
L. delbrueckii subsp. 
bulgaricus  DSM24734/SD5210  
L. plantarum  DSM24730/
SD5209  
B. longum  DSM24736/SD5220  
B. infantis  DSM24737/SD5219  
B. breve DSM24732/SD5206  
S. thermophilus  DSM24731/
SD5207Sachet 450B/sachet 1-4 sachetsII ğŸ 
(81,92)I ğŸ 
(82-84)I ğŸ 
(83,85-87)I  
(88-91,93-
94)
â„- Product requires refrigeration
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free9
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  General Health in Adult Population:
Brand Name Probiotic Strain(s) Dosage 
FormCFU/dose No. of 
doses/day
CID
OH
WM
LDL-C
M/A
BioGaiaÂ® ProDentisâ„¢ ğŸŒ¾ L. reuteri  ATCC PTA 5289  
L. reuteri  DSM 17938Lozenge 200M/lozenge 1 lozengeI ğŸ 
(63-67)
Calm BioticÂ® B. longum  R0175  
L. helveticus  R0052Capsule 3B/capsule 1 capsuleII  
(20-22)
CulturedCareÂ® Probiotic 
Gum with BLIS K12Â® ğŸŒ¾Streptococcus salivarius  K12 Lozenge 0.5B/lozenge 2-10 lozengesII ğŸ 
(61-62)
HMF Metabolic ğŸŒ¾â„L. acidophilus  CUL-60  
L. acidophilus  CUL-21  
B. animalis subsp. lactis  
CUL-34  
B. bifidum  CUL-20  
L. plantarum  CUL-66Capsule 50B/capsule 1 capsuleII ğŸ 
(54)
Purica Probiotic Cardio ğŸŒ¾ L. plantaru m CECT7257/
KABP011Â®  
L. plantaru m CECT7258/
KABP012Â®  
P. acidilactici CECT7259/
KABP013Â®Capsule 1B/capsule 1 capsuleII ğŸ 
(70-72)
Probiotic Sticks B. longum  R0175  
L. helveticus  R0052Stick 3B/stick 1 stickII ğŸ 
(20-22)
UltraFloraÂ® Control ğŸŒ¾B. animalis ssp. lactis  420 
(B420â„¢)Capsule 10B/capsule 1 capsuleI ğŸ 
(77)
UltraFloraÂ® Cold Support ğŸŒ¾L. plantarum  HEAL9  
L. paracasei 8700:2Capsule 1B/capsule 1 capsuleI ğŸ 
(79-80)
â„- Product requires refrigeration
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free
www.ProbioticChart.ca10
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Pediatric Population:
Brand Name Probiotic 
Strain(s)Dosage 
FormCFU/dose No. of 
doses/day
AAD
C
CE/AD
CID
Colic
FAP
IBS
ID
NEC*
OH
Regurg/ 
GI Mot
BioGaiaÂ® ProtectisÂ® Baby 
Drops ğŸŒ¾ L. reuteri  DSM 
17938Drops100M/5 
drops5 dropsI  
(107)I ğŸ 
(108-
109)II  
(114-
115)I  
(112-
113)I ğŸ 
(98-
101,116-
117)I  
(110-
111)I  
(110-
111)I ğŸ 
(102-
106)I  
(118-
120)I ğŸ 
(95-97)
BioGaiaÂ® ProtectisÂ® Drops 
with Vitamin D ğŸŒ¾ L. reuteri  DSM 
17938Drops100M/5 
drops5 dropsI  
(107)I ğŸ 
(108-
109)II  
(114-
115)I  
(112-
113)I ğŸ 
(98-
101,116-
117)I  
(110-
111)I  
(110-
111)I ğŸ 
(102-
106)I ğŸ 
(95-97)
BioGaiaÂ® ProtectisÂ® 
Chewable Tablets ğŸŒ¾
L. reuteri  DSM 
17938Chewable 
tablet100M/tablet 1 tablet
I  
(107)I ğŸ 
(108-
109)II  
(114-
115)I  
(112-
113)I  
(98-101)I  
(110-
111)I  
(110-
111)I ğŸ 
(102-
106)I  
(95-97)BioGaiaÂ® Junior Tablets 
with Vitamin D ğŸŒ¾ Chewable 
tablet100M/tablet 1 tablet
BioGaiaÂ® ProDentisâ„¢L. reuteri  ATCC PTA 
5289  
L. reuteri  DSM 
17938Lozenge200M/
lozenge1 lozengeI ğŸ 
(63-
67,157-
159)
CulturedCareÂ® Probiotic 
Gum with BLIS K12Â® ğŸŒ¾ Streptococcus 
salivarius  K12Lozenge 1B/lozenge 1-5 lozengesII ğŸ 
(61-62)
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free11
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Pediatric Population:
Brand Name Probiotic 
Strain(s)Dosage 
FormCFU/dose No. of 
doses/day
AAD
CDAD
CE/AD
CID
Colic
FAP
HP
IBS
ID
LH
NI
CulturelleÂ® Kids Daily 
Probiotic Chewables
L. rhamnosus  GGChewable 
tablet5B/tablet 2-4 tablets
I  
(127-
128)I  
(132-
138,143)I  
(142)I  
(129-
130)I  
(129-
130)I  
(121-
126,141)II  
(139-
140)I  
(131)CulturelleÂ® Kids Daily 
Probiotic PacketsPowder 5B/packet 2-4 packets
Ddrops Baby ğŸŒ¾ B. longum  
CECT7894/
KABP042Â®  
P. pentosaceus 
CECT8330/
KABP041Â®Drops 1B/5 drops 5 dropsI ğŸ 
(144)
FlorastorKidsÂ® ğŸŒ¾ Saccharomyces 
boulardii lyo  CNCM 
I-745Capsule  
Sachet5B/capsule  
5B/sachet1-2 capsules  
1-2 sachetsI ğŸ 
(150)III ğŸ 
(151)I ğŸ 
(45,152)I ğŸ 
(147-
149)
HMF Baby Drops ğŸŒ¾ B. longum  
CECT7894/ 
KABP042Â®  
P. pentosaceus 
CECT8330/ 
KABP041Â®Drops 1B/5 drops 5 dropsI ğŸ 
(144)
HMF Fit for School  
[50mg vitamin C, 1000IU 
vitamin D]  ğŸŒ¾L. acidophilus  
CUL-60  
L. acidophilus  
CUL-21  
B. animalis subsp. 
lactis CUL-34  
B. bifidum  CUL-20Chewable 
tablet  
Powder12.5B/tablet  
12.5B/scoop1 tablet  
1 scoopI ğŸ 
(153)
MetaKidsâ„¢ Baby Probiotic 
ğŸŒ¾L. rhamnosus  GG 
B. lactis BB-12Drops 1B/6 drops 6 dropsII  
(155)II ğŸ 
(154)
MetaKidsâ„¢ Probiotic ğŸŒ¾ L. acidophilus  
NCFMÂ®  
B. animalis subsp 
lactis Bi-07Â®Chewable 
tablet5B/tablet 2 tabletsI  
(156)
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free
www.ProbioticChart.ca12
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Pediatric Population:
Brand Name Probiotic Strain(s) Dosage 
FormCFU/dose No. of 
doses/day
CE/AD
CID
Colic
IBD-UC
IBS
ID
LH
NEC*
Orange Naturals Baby 
Probiotics +D3 Drops  
(400IU)  ğŸŒ¾â„L. rhamnosus  GG 
B. lactis  BB12Drops 2B/5 drops 5 dropsII  
(155)II  
(154)
Orange Naturals Probiotics 
Kids Chewable + Vitamin A, 
C, D3 ğŸŒ¾â„L. acidophilus  NCFM  
B. animalis subsp lactis  Bi-07Chewable 
tablet5B/tablet 1 tabletI  
(156)
ProZemaÂ® ğŸŒ¾ B. lactis BPL1 CECT 8145  
B. longum  ES1 CECT 7347  
L. casei BPL4 CECT 9104Stick 1.55B/stick 1 stickI ğŸ 
(160-
161)
Probiotic Baby B. lactis BB-12 Drops 1B/6 drops 6 dropsI  
(162)I  
(163)
Purica Probiotic Baby Colic 
ğŸŒ¾B. longum  CECT7894/KABP042Â®  
P. pentosaceus CECT8330/
KABP041Â®Drops 1B/5 drops 5 dropsI ğŸ 
(144)
Renew LifeÂ® FloraBaby B. breve HA-129  
L. rhamnosus  HA-111  
B. bifidum  HA-132  
B. infantis  HA-116  
B. longum  HA-135Powder 2B/scoop 1-2 scoopsII  
(145-
146)
Sisu Probiotic Kid Stiks ğŸŒ¾ L. helveticus  R0052  
B. infantis  R0033  
B. bifidum  R0071Stick 5B/stick 1 stickI  
(164-
165)
VisbiomeÂ® ğŸŒ¾â„     
This combination of strains is 
known as De Simone Formulation 
and is the same one listed in 
references that cite VSL#3 as 
treatment regimenL. acidophilus  DSM24735/SD5212  
L. paracasei DSM24733/SD5218  
L. delbrueckii subsp. bulgaricus  
DSM24734/SD5210  
L. plantarum  DSM24730/SD5209  
B. longum  DSM24736/SD5220  
B. infantis  DSM24737/SD5219  
B. breve DSM24732/SD5206  
S. thermophilus  DSM24731/SD5207Sachet 450B/sachet 1-2 sachetsI ğŸ 
(167-
168)I ğŸ 
(169)I  
(166)I  
(170)
â„- Product requires refrigeration
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free13
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Probiotic Products for  Maternal and Vaginal Health:
Brand Name Probiotic Strain(s) Dosage Form CFU/dose No. of doses/
dayBV Mastitis VC
MaternaÂ® Opti-LacÂ® 
Breast Feeding Support L. fermentum LC40â„¢ CECT5716 Capsule 3B/capsule 1 capsuleI ğŸ 
(55-56)
Probaclac BVÂ®L. acidophilus  A-212  
L. rhamnosus  A-119  
S. thermophilus  A-336Vaginal capsule 8B/capsule 1-2 capsulesII ğŸ 
(179)
ProvacareÂ®
L. rhamnosus  Lcr35 Vaginal ovule 3.41B/ovule 2 ovulesI ğŸ 
(181-183)I ğŸ 
(180)
RepHreshâ„¢ Pro-Bâ„¢ 
Probiotic ğŸŒ¾ L. rhamnosus  GR-1  
L. reuteri  RC-14Oral capsule0.5B each/
capsule2-4 capsulesI ğŸ 
(171,173-175,177-
178)I ğŸ 
(172,175-176)
UltraFloraÂ® Womenâ€™s ğŸŒ¾
L. reuteri  RC-14  
L. rhamnosus  GR-1Oral capsule 1B each/capsule 2 capsulesI ğŸ 
(171,173-175,177-
178)I ğŸ 
(172,175-176)
â„- Product requires refrigeration
ğŸ- Approved by Health Canada for listed indication; applicable to supplements  
ğŸŒ¾- Gluten Free14
www.ProbioticChart.ca
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023Functional Foods with Added Probiotics (Adults):
Brand Name Probiotic Strain(s) CFU/dose No. of doses/day AAD C CDAD CID IBS M/A
ActiviaÂ® â„ B. (animalis) lactis CNCM 
I-24941B/serving 1-3 servingsI  
(186)I  
(184-185)
DanActiveÂ® â„ L. casei sp. paracasei CNCM 
I-151810B/serving 1-2 servingsI  
(191,202)I  
(194-201)
GoodBellyÂ® Probiotic Juice 
DrinksL. plantarum  299v 20B/serving (8oz) 1 servingIII  
(31)III  
(32,36)I  
(33-35)
Yakult â„ L. casei Shirota 8B/bottle (80mL) 1-2 bottlesI  
(209-210)I  
(211-214)II  
(215-216)
Functional Foods with Added Probiotics (Children):
Brand Name Probiotic Strain(s) CFU/dose No. of doses/day AAD CID CMPA HP ID
DanActiveÂ® â„ L. casei sp. paracasei CNCM 
I-151810B/serving 1-2 servingsI   
(190,192-
193)I   
(189)II  
(187-188)
GerberÂ® Baby Cereals
B. lactis BB-121B/serving [serving=5 tbls] 1 serving
I  
(204)I  
(162,203)`GerberÂ® Toddler Cereals 1B/serving [serving=5 tbls] 1 serving
Good GrowÂ® Nutritional Toddler 
Drink1B/200mL serving 1 serving
Good Start Sootheâ„¢ Infant 
FormulaL. reuteri  DSM 17938 1M/gramRoutine feeding if an 
alternative to breast milk is 
requiredI  
(102-106)
Good StartÂ® Plus 1 Infant 
Formula
B. lactis BB-121M/gramRoutine feeding if an 
alternative to breast milk is 
requiredI  
(162,203)
Good StartÂ® Plus 2 Infant 
Formula  
(6 months+)130M/100mL servingRoutine feeding if an 
alternative to breast milk is 
requiredI  
(204)I  
(162,203)
NestlÃ©Â® NidoÂ® Nutritional 
Toddler DrinkB. lactis BB-12 1B/200mL serving 1 servingI  
(204)I  
(162,203)
NutramigenÂ® A+Â® with LGGÂ® 
Extensively hydrolyzed casein formula 
(EHCF)L. rhamnosus  GG  
[Branded LGG]1.35 x 10â· CFU per 100mL 
servingEHCF when an alternative 
to breast milk is requiredI  
(205-208)
â„- Product requires refrigeration15
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023References:
1Brenner, DM, and WD Chey. "Bifidobacterium Infantis 35624: A Novel Probiotic for the Treatment of IBS." Reviews in 
Gastroenterological Disorders 9.1 (2009): 7-15.  
2Quigley, EM, PJ Whorwell, L. Altringer, J. Morel, L. O'Mahony, and F. Shanahan. "Probiotic Use Results in Normalization of 
Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium Infantis 35624." 
American Journal of Gastroenterology 100.S9 (2005): S326.
3Whorwell, P., L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O'Mahony, B. Kiely, F. Shanahan, and EM Quigley. 
"Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome." 
American Journal of Gastroenterology 101 (2006): 1581-590.
4O'Mahony, L., J. Mccarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O'Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. 
M. Quigley. "Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to 
Cytokine Profiles." Gastroenterology 128.3 (2005): 541-51.
5Beausoleil, M., N. Fortier, S. Guenette, A. L'Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. "Effect of a 
Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Caseiin the Prevention of Antibiotic-
Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial." Canadian Journal of Gastroenterology 21.11 
(2007): 732-36.
6Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. "Dose-Response Efficacy of a Proprietary Probiotic 
Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and 
Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients." American Journal of Gastroenterology 105.7 
(2010): 1636-641.
7Sampalis, J., E. Psaradellis, and E. Rampakakis. â€œEfficacy of BIO K+ CL1285Â® in the Reduction of Antibiotic-Associated 
Diarrhea â€“ a Placebo Controlled Double-Blind Randomized, Multi-Center Study.â€ Archives of Medical Science: AMS 6.1 
(2010): 56â€“64.  
8Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. "Probiotics for the 
Prevention of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis." Annals of Internal 
Medicine 157.12 (2012): 878
9Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. "Is Primary 
Prevention of Clostridium Difficile Infection Possible with Specific Probiotics?" International Journal of Infectious 
Diseases 6.11 (2012): E786-792.  
10McFarland, L.V., N. Ship, J. Auclair and M. Millette. "Primary prevention of Clostridium difficile infections with a specific 
probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence " Journal of 
Hospital Infection 99.4 (2018):443-452.
11Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. "Efficacy and Safety of Lactobacillus Reuteri 
ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or 
Folfox Schedule." Annals of Oncology. S9 ed. Vol. 19. (2008).
12Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and 
J. Katz. "A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the 
Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults." Journal of Clinical Gastroenterology 45.9 (2011): 
785-89.
13Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. 
Gasbarrini, and A. Gasbarrini. "Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-
Related." Digestive and Liver Disease 40 (2008)
14Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, 
E. Ierardi, and V. L. Miniello. "Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 
and Effect on Eradication Therapy: A Pilot Study." Helicobacter 13.2 (2008): 127-34.
15Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. "Lactobacillus Reuteri Tablets Suppress 
Helicobacter Pylori Infection--a Double-blind Randomised Placebo-controlled Cross-over Clinical Study." Journal of the 
Japanese Association for Infectious Diseases 81.4 (2007): 387-93.
16Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. "Helicobacter Pylori Eradication with 
Lactobacillus Reuteri: A Double Blind Placebo-controlled Study." Dig Liver Dis 37.Suppl 1 (2005): S88.
17Ojetti, V., G. Ianiro, A. Tortora, G. D'Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. "The Effect of 
Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Constipation: A Randomized, Double-Blind, 
Placebo-Controlled Trial."Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
18Preston, K., R. Krumian, J. Hattner, D. de Montigny, M. Stewart and S. Gaddam. "Lactobacillus acidophilus CL1285, 
Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-
blind, randomised, placebo-controlled study." Beneficial Microbes 9.5 (2018): 697-706.19Majeed, Muhammed et al.: "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea 
predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study." Nutrition 
journal vol. 15 21. 27 Feb. 2016, doi:10.1186/s12937-016-0140-6
20Huang R., H. Ning, L. Yang, C. Jia, F. Yang, G. Xu, and H. Tan. "Efficacy of Probiotics on Anxiety: A Meta-analysis of 
Randomized Controlled Trials." Neuropsychiatry 7.6 (2017): 862-71.
21Messaoudi M., R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel, and J. 
Cazaubiel. "Assessment of Psychotropic-like Properties of a Probiotic Formulation ( Lactobacillus Helveticus R0052 and 
Bifidobacterium Longum R0175) in Rats and Human Subjects." British Journal of Nutrition 105.05 (2010): 755-64.
22Messaoudi M., N.Violle, J. Bisson, D. Desor, H. Javelot, and C. Rougeot. "Beneficial Psychological Effects of a Probiotic 
Formulation (Lactobacillus HelveticusR0052 AndBifidobacterium LongumR0175) in Healthy Human Volunteers." Gut 
Microbes 2.4 (2011): 256-61.
23Kale-Pradhan, P. B., H. K. Jassal, and S. M. Wilhelm. "Role of Lactobacillus in the Prevention of Antibiotic-Associated 
Diarrhea: A Meta-analysis." Pharmacotherapy 30.2 (2010): 119-26.
24Armuzzi, A., F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Anti, A. De Lorenzo, P. 
Pola, G. Gasbarrini, and A. Gasbarrini. "The Effect of Oral Administration of Lactobacillus GG on Antibiotic-associated 
Gastrointestinal Side-effects during Helicobacter Pylori Eradication Therapy." Alimentary Pharmacology and 
Therapeutics 15.2 (2001): 163-69.
25Gorbach, S. L., Chang, T. W. & Goldin, B. "Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus 
GG." Lancet 2, 1519 (1987).
26Bennet RG, Gorbach SL et al. "Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG" Nutr Today 
Suppl Vol 31 No 6 Nov/Dec 1996
27Morrow, L. E., Kollef, M. H. & Casale, T. B. "Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, 
randomized, controlled trial." American journal of respiratory and critical care medicine 182, 1058-1064 (2010).
28Gosselink MP, Schouten WR et al. "Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus 
rhamnosus GG" Dis Colon Rectum 2004; 47: 876-84
29Oksanen, P.J., et al. "Prevention of travellersâ€™ diarrhoea by Lactobacillus GG." Annals of medicine, 1990. 22(1): p. 53-56.
30Hilton, E., et al. "Efficacy of Lactobacillus GG as a diarrheal preventive in travelers." Journal of travel medicine, 1997. 4(1): 
p. 41-43.
31Lonnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. "Intake of Lactobacillus Plantarum 
Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics." Journal of Clinical Gastroenterology 
44.2 (2010): 106-12.
32Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. "Lactobacillus Plantarum 299v Reduces 
Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics." Acta Anaesthesiologica 
Scandinavica 52.8 (2008): 1096-102.
33Niedzielin, K., H. Kordecki, and B. Birkenfeld. "A Controlled, Double-blind, Randomized Study on the Efficacy of 
Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome." European Journal of Gastroenterology and 
Hepatology 13.10 (2001): 1143-147.
34Nobaek, S., M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. "Alteration of Intestinal Microflora Is Associated 
with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome." The American Journal of 
Gastroenterology 95.5 (2000): 1231-238.
35Ducrotte, P., P. D. Sawant, and V. Jayanthi. "Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms 
of Irritable Bowel Syndrome." World Journal of Gastroenterology 18.30 (2012): 4012-018.
36Kujawa-Szewieczek, A.; Adamczak, M.; KwiecieÅ„, K.; Dudzicz, S.; Gazda, M.; WiÄ™cek, A. "The Effect of Lactobacillus 
plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics." 
Nutrients 2015, 7, 10179-10188
37Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. "Prophylactic Saccharomyces Boulardii in the 
Prevention of Antibiotic-associated Diarrhea: A Prospective Study." Medical Science Monitor 12.4 (2006): PI19-22.
38Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. 
Bowen, D. Borjal, and G. W. Elmer. "The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of 
High Dose Vancomycin Combined WithSaccharomyces Boulardii." Clinical Infectious Diseases 31.4 (2000): 1012-017.
39Mcfarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. 
Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. "A Randomized Placebo-controlled Trial of Saccharomyces 
Boulardii in Combination with Standard Antibiotics for Clostridium Difficile Disease." JAMA: The Journal of the American 
Medical Association 271.24 (1994): 1913-918.
40Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. "Prevention of travellerâ€™s diarrhea: comparison of different 
non-antibiotic preparations." Travel Med Int 11 (1989): 9-17.
41Kollaritsch, H., H. Holst, P. Grobara, and G. Wiedermann. "Prophylaxis of traveller's diarrhoea with Saccharomyces 
boulardii." Fortschr Med 111 (1993): 152-156. (Article in German)
Clinical Guide to Probiotic Products Available in Canada 15th Edition 202342McFarland, L. V. "Meta-analysis of probiotics for the prevention of traveler's diarrhea." Travel medicine and infectious 
disease 5.2 (2007): 97-105.
43Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. "Saccharomyces boulardii in maintenance treatment of Crohnâ€™s 
disease." Digestive diseases and sciences 45.7 (2000): 1462-1464.
44Song, M. J., D.I Park, J.H. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, and B.I. Kim. "The Effect of Probiotics and 
Mucoprotective Agents on PPIâ€Based Triple Therapy for Eradication of Helicobacter pylori." Helicobacter 15.3 (2010): 
206-213.
45Szajewska, H., A. Horvath, and A. Piwowarczyk. "Metaâ€analysis: the effects of Saccharomyces boulardii supplementation 
on Helicobacter pylori eradication rates and side effects during treatment." Alimentary pharmacology & therapeutics 
32.9 (2010): 1069-1079.
46Cindoruk, M., G. Erkan,T. Karakan, A. Dursun, and S. Unal. "Efficacy and Safety of Saccharomyces boulardii in the 
14â€day Triple Antiâ€Helicobacter pylori Therapy: A Prospective Randomized Placeboâ€Controlled Doubleâ€Blind Study." 
Helicobacter 12.4 (2007): 309-316.
47Guslandi, M., Giollo, P., and Testoni, P. "(2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis." European 
Journal Of Gastroenterology And Hepatology 15, 697-698.
48Sivananthan, K., and Petersen, A. "(2018). Review of Saccharomyces boulardii as a treatment option in IBD." 
Immunopharmacology And Immunotoxicology 40, 465-475.
49Tang, H., Wu, H., Mao, J., Zhu, L., Li, N., and Wang, Y. "(2014). Clinical study on saccharomyces boulardii in the treatment 
of patients with mild to moderate ulcerative colitis." 11Th IEEE International Conference On Control And Automation 
(ICCA).
50Zhou, W. "(2017). Saccharomyces boulardii powder combined with mesalazine for treatment of active ulcerative colitis: 
Curative effect and impact on fecal calprotectin and serum inflammatory factors." World Chinese Journal Of Digestology 
25, 2065.
51Flatley EA, Wilde AM, Nailor MD. "Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile 
infection." J Gastrointestin Liver Dis. 2015;24(1):21â€“24
52Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. "Clostridium difficile pilot study: effects of probiotic 
supplementation on the incidence of C. difficile diarrhoea." International Microbiology 7.1 (2010): 59-62.
53Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. "Clinical trial: a multistrain 
probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a doubleâ€blind placeboâ€controlled 
study." Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.
54Michael, D.R., Jack, A.A., Masetti, G. et al. "A randomised controlled study shows supplementation of overweight and 
obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being." Sci Rep 10, 4183 (2020). 
https://doi.org/10.1038/s41598-020-60991-7
55Maldonado-LobÃ³n, Jose A et al. "Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk 
of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial." Breastfeeding medicine : the official journal 
of the Academy of Breastfeeding Medicine vol. 10,9 (2015): 425-32.
56Arroyo, Rebeca et al. "Treatment of infectious mastitis during lactation: antibiotics versus oral administration of 
Lactobacilli isolated from breast milk." Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America vol. 50,12 (2010): 1551-8. doi:10.1086/652763
57Floch, Martin H. "Probiotic therapy for ulcerative colitis." Journal of clinical gastroenterology 44.4 (2010): 237-238.
58Henker, J., S. MÃ¼ller, M.W Laass, A. Schreiner, and J. Schulze. "Probiotic Escherichia coli Nissle 1917 (EcN) for successful 
remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study." Zeitschrift fuer 
Gastroenterologie 46.09 (2008): 874-875.
59Kruis, W., E. SchÃ¼tz, P. Fric, B. Fixa, G. Judmaier, and M. Stolte. "Doubleâ€blind comparison of an oral Escherichia coli 
preparation and mesalazine in maintaining remission of ulcerative colitis." Alimentary pharmacology & therapeutics 11.5 
(1997): 853-858.
60Kruis, W., P. FriÄ, J. Pokrotnieks, M. LukÃ¡Å¡, B. Fixa, M. KaÅ¡ÄÃ¡k, M.A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, and C. 
Wolff. "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with 
standard mesalazine." Gut 53.11 (2004): 1617-1623.
61Burton, J. P., C. N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg.. "A preliminary study of the effect of probiotic 
Streptococcus salivarius K12 on oral malodour parameters." Journal of applied microbiology 100.4 (2006): 754-764.
62Di Pierro, F, G. Donato, F. Fomia, T. Adami, D. Careddu, C. Cassandro, and R. Albera. "Preliminary pediatric clinical 
evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused 
by Streptococcus pyogenes and recurrent acute otitis media." International journal of general medicine 5 (2012): 991.
63Schlagenhauf U, Jakob L et al. "Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy 
gingivitis: an RCT." J Clin Periodontol. 2016 Nov;43(11):948-954
64Teughels W, Durukan A, et al. "Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of 
chronic periodontitis: a randomized placebo-controlled study." J Clin Periodontol 2013; 40: 1025â€“103565GalofrÃ© M, Palao D, Vicario M, Nart J, Violant D. "Clinical and microbiological evaluation of the effect of Lactobacillus 
reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial." J Periodontal Res. 2018 
Jun;53(3):378-390.
66Kraft-Bodi E, JÃ¸rgensen M, Keller MK. "Effect of Probiotic Bacteria on Oral Candida in Frail Elderly." J Dent Res. 2015 
Sep;94(9 Suppl):181S-6S
67Tekce M, Ince G, Gursoy H, et al. "Clinical and microbiological effects of probiotic lozenges in the treatment of chronic 
periodontitis: a 1-year follow-up study." J Clin Periodontol 2015; 42: 363â€“372
68Agraib, Lana M et al. â€œProbiotic supplementation induces remission and changes in the immunoglobulins and 
inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study.â€ 
Clinical nutrition ESPEN vol. 51 (2022): 83-91. doi:10.1016/j.clnesp.2022.08.020
69Benes, K., A. Kretk, and Thomas A. Tompkins. "A probiotic combination for IBS. A pilot clinical study." NutraFoods 5.1 
(2006): 20-27.
70Fuentes, Mari C et al. â€œCholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in 
hypercholesterolaemic adults.â€ The British journal of nutrition vol. 109,10 (2013): 1866-72.
71Kerlikowsky F, Greupner T, MÃ¼ller M, Mazo JE, MÃ¼ller HJ, Hahn A. Probiotic formulation influences blood cholesterol 
levels: a randomized, controlled trial during the covid19 pandemic. Clin Nutr ESPEN. 2021
72Fuentes, Mari C., et al. "A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for 
lowering cholesterol." Mediterranean Journal of Nutrition and Metabolism 9.2 (2016): 125-135.
73Lorenzo-ZÃºÃ±iga, Vicente et al. â€œI.31, a new combination of probiotics, improves irritable bowel syndrome-related quality 
of life.â€ World journal of gastroenterology vol. 20,26 (2014): 8709-16.
74Barraza-Ortiz, Diego A et al. â€œCombination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces 
Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study.â€ Digestive diseases (Basel, Switzerland) vol. 39,3 
(2021): 294-300. doi:10.1159/000510950
75A.C. Ouwehand et al. "Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response 
study." Vaccine 32 (2014) 458â€“463
76Engelbrektson A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL. "Probiotics to minimize the 
disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy." J Med Microbiol. 2009 May;58(Pt 
5):663-670. doi: 10.1099/jmm.0.47615-0. PMID: 19369530.
77Stenman L. K., Lehtinen M.J., Meland N., Christensen J.E., Yeung N., Saarinen M.T.,Courtney M., Burcelin R., LÃ¤hdeaho 
M., Linros J., Apter D., Scheinin M., Kloster Smerud H, Rissanen A., and Lahtinen S.. "Probiotic With or Without Fiber 
Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adultsâ€”Randomized Controlled 
Trial." EBioMedicine 13 (2016): 190-200.
78Ringel-Kulka T, Palsson OS, Maier D, et al. "Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis 
Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders." Journal of Clinical 
Gastroenterology. 2011;45(6):518â€“525
79Berggren, A., I. L. AhrÃ©n, N. Larsson, and G. Ã–nning. "Randomised, double-blind and placebo-controlled study using new 
probiotic lactobacilli for strengthening the body immune defence against viral infections." European journal of nutrition 
50.3 (2011): 203-210.
80Regina, B., G. Joerg, and D. Steffi. "Randomized, Double Blind and Placebo Controlled Study Using a Combination of 
Two Probiotic Lactobacilli to Alleviate Symptoms and Frequency of Common Cold." Food and Nutrition Sciences 2013 
(2013).
81Parkes, G. C., D. Chatoor, and A. Emmanuel. "The probiotic VSL# 3 increases scbm and reduces symptom severity 
scores in patients with functional constipation." Gut 60.Suppl 1 (2011): A163-A163
82Sood, A., V. Midha, G.K. Makharia, V. Ahuja, D. Singal, P. Goswami, and R.K. Tandon. "The probiotic preparation, VSL# 
3 induces remission in patients with mild-to-moderately active ulcerative colitis." Clinical Gastroenterology and 
Hepatology 7.11 (2009): 1202-1209.
83Tursi, A., G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, and A. Gigliobianco. "Low-dose balsalazide plus a high-
potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-
moderate ulcerative colitis." Medical Science Monitor 10.11 (2004): PI126-PI131.
84Tursi, A., G. Brandimarte, A. Papa, A. Giglio, W. Elisei, G.M. Giorgetti, G. Forti, S. Morini, C. Hassan, M.A. Pistoia, and 
M.E. Modeo. "Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a 
Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study." The American Journal of 
Gastroenterology 105.10 (2010): 2218-2227.
85Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, and M. Campieri."Oral 
bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial." 
Gastroenterology 119.2 (2000): 305-309.
86Gionchetti, P., F. Rizzello, U. Helwig, A. Venturi, K. M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli, and 
M. Campieri. "Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial." 
Gastroenterology 124.5 (2003): 1202-1209.
Clinical Guide to Probiotic Products Available in Canada 15th Edition 202387Mimura, T., F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri, and M. A. 
Kamm. "Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis." 
Gut 53.1 (2004): 108-114.
88Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label 
randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol. 2012;107:1043â€“1050.
89Shukla S., Shukla A., Mehboob S., et al. "Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics 
and synbiotics on minimal hepatic encephalopathy." Alimen Pharmacol Ther. 2011;33:662â€“671.
90Mittal, V.V. et al. "A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment 
of minimal hepatic encephalopathy." European Journal of Gastroenterology and Hepatology. 2011, 23:725â€“732
91Lunia, M.K. et al."Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial." 
Clinical Gastroenterology and Hepatology. 2014 Jun;12(6):1003-8
92Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, Jung KW, Koo HS, Myung SJ "Constipation Research group of Korean 
Society of Neurogastroenterology and Motility. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 
Probiotic Treatment in Patients With Functional Constipation." J Neurogastroenterol Motil. 2015 Jan 1;21(1):111-20. doi: 
10.5056/jnm14048. PMID: 25537674; PMCID: PMC4288088.
93Duseja, Ajay et al.: "High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease 
(NAFLD): a randomised, double-blind, proof of concept study." BMJ open gastroenterology vol. 6,1 e000315. 7 Aug. 
2019, doi:10.1136/bmjgast-2019-000315
94RomÃ¡n, Eva et al.: "Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A 
Randomized Trial." Hepatology communications vol. 3,5 632-645. 12 Mar. 2019, doi:10.1002/hep4.1325
95Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, L. Cavallo, and R. Francavilla. "The effects of probiotics on feeding 
tolerance, bowel habits, and gastrointestinal motility in preterm newborns." The Journal of pediatrics 152.6 (2008): 
801-806.
96Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, A. Filannino, L. Cavallo, and R. Francavilla. "Lactobacillus reuteri 
accelerates gastric emptying and improves regurgitation in infants." European journal of clinical investigation 41.4 (2011): 
417-422.
97Garofoli, F., E. Civardi, F. Indrio, I. Mazzucchelli, M. Angelini, C. Tinelli, and M. Stronati. "The early administration of 
Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants." International journal of 
food sciences and nutrition 65.5 (2014): 646-648.
98Savino, F., E. Pelle, E. Palumeri, R. Oggero, and R. Miniero. "Lactobacillus reuteri (American Type Culture Collection Strain 
55730) versus simethicone in the treatment of infantile colic: a prospective randomized study." Pediatrics 119.1 (2007): 
e124-e130.
99Savino, F., L. Cordisco, V. Tarasco, E. Palumeri, R. Calabrese, R. Oggero, S. Roos, and D. Matteuzzi.  "Lactobacillus reuteri 
DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial." Pediatrics 126.3 (2010): e526-e533.
100Sung, V., H. Hiscock, M.L.K. Tang, F.K. Mensah, M.L. Nation, C. Satzke, R.G. Heine, A. Stock, R.G. Barr, and M. Wake. 
"Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial." BMJ 348 
(2014): g2107.
101Chau, K., E. Lau, S. Greenberg, S. Jacobson, P. Yazdani-Brojeni, N. Verma, and G. Koren. "Probiotics for infantile colic: 
a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938." The Journal of 
pediatrics 166.1 (2015): 74-78.
102Eom, T.H., E.Y. Oh, Y.H. Kim, H.S. Lee, P.S. Jang, D.U. Kim, J.T. Kim, and B.C. Lee."The therapeutic effect of Lactobacillus 
reuteri in acute diarrhea in infants and toddlers." Korean Journal of Pediatrics 48.9 (2005): 986-990.
103Shornikova, A.V., I.A. Casas, E. Isolauri, H. MykkÃ¤nen, and T. Vesikari. "Lactobacillus reuteri as a therapeutic agent in 
acute diarrhea in young children." Journal of pediatric gastroenterology and nutrition 24.4 (1997): 399-404.
104Agustina, R, F.J. Kok, O. van de Rest, U. Fahmida, A. Firmansyah, W. Lukito, E.J.M Feskens, E.G.H.M van den Heuvel, R. 
Albers, and I.M.J. Bovee-Oudenhoven.  "Randomized trial of probiotics and calcium on diarrhea and respiratory tract 
infections in Indonesian children." Pediatrics 129.5 (2012): e1155-e1164.
105Francavilla, R., E. Lionetti, S. Castellaneta, F. Ciruzzi, F. Indrio, A. Masciale, C. Fontana, M. M. La Rosa, L. Cavallo, and A. 
Francavilla.  "Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoeaâ€a 
doubleâ€blind study." Alimentary pharmacology & therapeutics 36.4 (2012): 363-369.
106Dinleyici, E.C., and Y. Vandenplas. "Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea 
in hospitalised children." Acta Paediatrica 103.7 (2014): e300-e305.
107Lionetti, E., V. L. Miniello, S. P. Castellaneta, A. M. Magista, A. De Canio, G. Maurogiovanni, E. Ierardi, L. Cavallo, and R. 
Francavilla. "Lactobacillus reuteri therapy to reduce sideâ€effects during antiâ€Helicobacter pylori treatment in children: a 
randomized placebo controlled trial." Alimentary pharmacology & therapeutics 24.10 (2006): 1461-1468.
108Coccorullo, P., C. Strisciuglio, M. Martinelli, E. Miele, L. Greco, and A. Staiano."Lactobacillus reuteri (DSM 17938) in 
infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study." The Journal of 
pediatrics 157.4 (2010): 598-602.
109Indrio, F., A. Di Mauro, G. Riezzo, E. Civardi, C. Intini, L. Corvaglia, E. Ballardini, M. Bisceglia, M. Cinquetti, E. Brazzoduro, 
and A. Del Vecchio. "Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: 
a randomized clinical trial." JAMA pediatrics 168.3 (2014): 228-233.
110Romano, C., V. Ferrau, F. Cavataio, G. Iacono, M. Spina, E. Lionetti, F. Comisi, A. Famiani, and D. Comito."Lactobacillus 
reuteri in children with functional abdominal pain (FAP)." Journal of paediatrics and child health 50.10 (2014): E68-E71.111Weizman, Z. "A Randomized Controlled Trial of Lactobacillus reuteri DSM 17938 in Functional abdominal pain of 
childhood." SP-N-0102, Nutrition Trial symposia within the ESPGHAN program (9-12th of June, 2014 presented at 47th 
Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, in Jerusalem).
112Weizman, Z., G. Asli, and A. Alsheikh. "Effect of a probiotic infant formula on infections in child care centers: comparison 
of two probiotic agents." Pediatrics 115.1 (2005): 5-9.
113Gutierrez-Castrellon, P., G. Lopez-Velazquez, L. Diaz-Garcia, C. Jimenez-Gutierrez, J. Mancilla-Ramirez, J. Estevez-
Jimenez, and M. Parra. "Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial." 
Pediatrics 133.4 (2014): e904-e909.
114Abrahamsson, T.R., T. Jakobsson, M.F. BÃ¶ttcher, M. Fredrikson, M.C. Jenmalm, B. BjÃ¶rkstÃ©n, and G. Oldaeus. "Probiotics 
in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial." Journal of Allergy and 
Clinical Immunology 119.5 (2007): 1174-1180.
115Forsberg et al. "Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants" Clinical 
and Translational Allergy 2014, 4:21
116Mi GL, Zhao L et al. "Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a 
prospective single blind randomized trial." Antonie Van Leeuwenhoek. 2015 Jun;107(6):1547-53.
117Szajewska, Hania, et al. "Lactobacillus Reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A 
Randomized, Double-Blind, Placebo-Controlled Trial." The Journal of Pediatrics, vol. 162, no. 2, Feb. 2013, pp. 257â€“262, 
doi:10.1016/j.jpeds.2012.08.004.
118Hunter, C., M.V.T Dimaguila, P. Gal, J.E. Wimmer, J.L. Ransom, R.Q. Carlos, M. Smith, and C.C. Davanzo. "Effect of routine 
probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight< 1000 
grams: a sequential analysis." BMC pediatrics 12.1 (2012): 1.
119Athalye-Jape, Gayatri, et al. "Lactobacillus Reuteri DSM 17938 as a Probiotic for Preterm Neonates : A Strain-
Specific Systematic Review." Journal of Parenteral and Enteral Nutrition, vol. 40, no. 6, Aug. 2016, pp. 783â€“794, 
doi:10.1177/0148607115588113.
120Dimaguila M, Gal P, Wilson T, Wimmer Jr J, Smith Mc, Carlos R, Davanzo C, Ransom J. "Pharmacoeconomic impact of use 
of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight 
infants." Research and Reports in Neonatology. 2013;3:21-25 https://doi.org/10.2147/RRN.S43272
121Szajewska, H., and J.Z. Mrukowicz. "Probiotics in the treatment and prevention of acute infectious diarrhea in infants 
and children: a systematic review of published randomized, double-blind, placebo-controlled trials." Journal of pediatric 
gastroenterology and nutrition 33 (2001): S17-S25.
122Basu, S., M. Chatterjee, S. Ganguly, and P.K. Chandra. "Efficacy of Lactobacillus rhamnosus GG in acute watery 
diarrhoea of Indian children: a randomised controlled trial." Journal of paediatrics and child health 43.12 (2007): 837-842.
123Basu, S., D.K. Paul, S. Ganguly, M. Chatterjee, and P.K. Chandra.  "Efficacy of high-dose Lactobacillus rhamnosus 
GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial." Journal of clinical 
gastroenterology 43.3 (2009): 208-213.
124Guandalini, S., L. Pensabene, M.A. Zikri, J.A Dias, L.G. Casali, H. Hoekstra, S. Kolacek, K. Massar, D. Miceticâ€“Turk, A. 
Papadopoulou, and J.S. de Sousa. "Lactobacillus GG administered in oral rehydration solution to children with acute 
diarrhea: a multicenter European trial." Journal of pediatric gastroenterology and nutrition 30.1 (2000): 54-60.
125Ritchie, B.K., D.R. Brewster, C.D. Tran, G.P. Davidson, Y. McNeil, and R.N. Butler. "Efficacy of Lactobacillus GG in 
aboriginal children with acute diarrhoeal disease: a randomised clinical trial." Journal of pediatric gastroenterology and 
nutrition 50.6 (2010): 619-624.
126Misra, S., T.K. Sabui, and N.K. Pal. "A randomized controlled trial to evaluate the efficacy of lactobacillus GG in infantile 
diarrhea." The Journal of pediatrics 155.1 (2009): 129-132.
127Vanderhoof, J.A., D.B. Whitney, D.L. Antonson, T.L. Hanner, J.V. Lupo, and R.J. Young."Lactobacillus GG in the prevention 
of antibiotic-associated diarrhea in children." The Journal of pediatrics 135.5 (1999): 564-568.
128Johnston, B.C., J.Z. Goldenberg, P.O. Vandvik, X. Sun, and G.H. Guyatt. "Probiotics for the prevention of pediatric 
antibioticâ€associated diarrhea."  The Cochrane Library  (2011).
129GawroÅ„ska, A., P. Dziechciarz, A. Horvath, and H. Szajewska. "A randomized doubleâ€blind placeboâ€controlled trial of 
Lactobacillus GG for abdominal pain disorders in children." Alimentary pharmacology & therapeutics 25.2 (2007): 177-
184.
130Francavilla R., V. Miniello, A.M. MagistÃ , A. De Canio, N. Bucci, F. Gagliardi, E. Lionetti, S. Castellaneta, L. Polimeno, 
L. Peccarisi, and F. Indrio. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal 
pain." Pediatrics 126.6 (2010): e1445-e1452.
129GawroÅ„ska, A., P. Dziechciarz, A. Horvath, and H. Szajewska. "A randomized doubleâ€blind placeboâ€controlled trial 
of Lactobacillus GG for abdominal pain disorders in children." Alimentary pharmacology & therapeutics 25.2 (2007): 
177-184.
130Francavilla R., V. Miniello, A.M. MagistÃ , A. De Canio, N. Bucci, F. Gagliardi, E. Lionetti, S. Castellaneta, L. Polimeno, 
L. Peccarisi, and F. Indrio. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal 
pain." Pediatrics 126.6 (2010): e1445-e1452.
131Hojsak, I., S. AbdoviÄ‡, H. Szajewska, M. MiloÅ¡eviÄ‡, Å½. KrznariÄ‡, and S. KolaÄek. "Lactobacillus GG in the prevention of 
nosocomial gastrointestinal and respiratory tract infections." Pediatrics 125.5 (2010): e1171-e1177.
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023132Doege, K., D. Grajecki, B.C. Zyriax, E. Detinkina, C. zu Eulenburg, and K.J. Buhling."Impact of maternal supplementation 
with probiotics during pregnancy on atopic eczema in childhoodâ€“a meta-analysis." British journal of nutrition 107.01 
(2012): 1-6.
133KalliomÃ¤ki, M., S. Salminen, H. Arvilommi, P. Kero, P. Koskinen, and E. Isolauri "Probiotics in primary prevention of atopic 
disease: a randomised placebo-controlled trial." The Lancet 357.9262 (2001): 1076-1079.
134Rautava, S., M. KalliomÃ¤ki, and E. Isolauri. "Probiotics during pregnancy and breast-feeding might confer 
immunomodulatory protection against atopic disease in the infant." Journal of Allergy and Clinical Immunology 109.1 
(2002): 119-121.
135KalliomÃ¤ki, M., S. Salminen, T. Poussa, H. Arvilommi, and E. Isolauri. "Probiotics and prevention of atopic disease: 4-year 
follow-up of a randomised placebo-controlled trial." The Lancet 361.9372 (2003): 1869-1871.
136KalliomÃ¤ki, M., S. Salminen, T. Poussa, and E. Isolauri.  "Probiotics during the first 7 years of life: a cumulative risk 
reduction of eczema in a randomized, placebo-controlled trial." Journal of Allergy and Clinical Immunology 119.4 (2007): 
1019-1021.
137Dotterud, C. K., O. StorrÃ¸, R. Johnsen, and T. Ã˜ien. "Probiotics in pregnant women to prevent allergic disease: a 
randomized, doubleâ€blind trial." British Journal of Dermatology 163.3 (2010): 616-623.
138Boyle, R. J., I. H. Ismail, S. Kivivuori, P. V. Licciardi, R. M. Robinsâ€Browne, Lâ€J. Mah, C. Axelrad, S. Moore, S. Donath, J.B. 
Carlin, and S.J. Lahtinen. "Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized 
controlled trial." Allergy 66.4 (2011): 509-516.
139Lavekar, A.S., D.V. Raje, T. Manohar, and A.A. Lavekar. "Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver 
Disease: A Meta-analysis." Euroasian J Hepato-Gastroenterol 7.2 (2017): 130-37.
140Vajro P., C. Mandato, M.R. Licenziati, A. Franzese, D.F. Vitale, S. Lenta, M. Caropreso, G.Vallone, and R.Meli. "Effects of 
Lactobacillus Rhamnosus Strain GG in Pediatric Obesity-related Liver Disease." Journal of Pediatric Gastroenterology 
and Nutrition 52.6 (2011): 740-43.
141Szajewska H, Kolodziej M, et al. "Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute 
gastroenteritis in children â€“ a 2019 update." Aliment Pharmacol Ther. 2019;00:1â€“9.
142Hojsak I, Snovak N et al. "Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in 
children who attend day care centers: A randomized, double-blind, placebo-controlled trial" Clinical Nutrition 29 (2010) 
312â€“316
143Carucci, Laura et al. â€œTherapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with 
atopic dermatitis. The results of the ProPAD trial.â€ Pediatric allergy and immunology : official publication of the European 
Society of Pediatric Allergy and Immunology vol. 33,8 (2022): e13836. doi:10.1111/pai.13836
144Chen, Ke et al. â€œInfantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus 
CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial.â€ Frontiers in pediatrics vol. 9 (2009) 635176.
145Janvier, A., J. Malo, and K.J. Barrington. "Cohort study of probiotics in a North American neonatal intensive care 
unit." The Journal of pediatrics 164.5 (2014): 980-985.
146Samara, Jumana et al. â€œSupplementation with a probiotic mixture accelerates gut microbiome maturation and reduces 
intestinal inflammation in extremely preterm infants.â€ Cell host & microbe vol. 30,5 (2022): 696-711.e5. doi:10.1016/j.
chom.2022.04.005
147Htwe, K., K.S. Yee, M. Tin, and Y. Vandenplas "Effect of Saccharomyces boulardii in the treatment of acute watery 
diarrhea in Myanmar children: a randomized controlled study." The American journal of tropical medicine and 
hygiene 78.2 (2008): 214-216.
148KurugÃ¶l, Z., and G. KoturoÄŸlu. "Effects of Saccharomyces boulardii in children with acute diarrhoea." Acta 
Paediatrica 94.1 (2005): 44-47.
149Feizizadeh, S., A. Salehi-Abargouei, and V. Akbari. "Efficacy and safety of Saccharomyces boulardii for acute 
diarrhea." Pediatrics (2014): peds-2013.
150Kotowska, M., P. Albrecht, and H. Szajewska. "Saccharomyces boulardii in the prevention of antibioticâ€associated 
diarrhoea in children: a randomized doubleâ€blind placeboâ€controlled trial." Alimentary pharmacology & therapeutics 21.5 
(2005): 583-590.
151Buts, J.P., G. Corthier, and M. Delmee. "Saccharomyces boulardii for Clostridium difficile-associated enteropathies in 
infants." Journal of pediatric gastroenterology and nutrition 16.4 (1993): 419-425.
152Bin, Zhang, et al. "The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori 
eradication treatment in children." Pediatric gastroenterology, hepatology and nutrition 18.1 (2015): 17-22.
153Garaiova, I., J. MuchovÃ¡, Z. NagyovÃ¡, Duolao Wang, J. V. Li, Z. OrszÃ¡ghovÃ¡, D. R. Michael, S. F. Plummer, and Z. 
ÄuraÄkovÃ¡. "Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a 
randomised controlled pilot study." European journal of clinical nutrition 69.3 (2015): 373-379.
154Rautava, S., S. Salminen, and E. Isolauri. "Specific probiotics in reducing the risk of acute infections in infancyâ€“a 
randomised, double-blind, placebo-controlled study." British Journal of Nutrition 101.11 (2009): 1722-1726.
155Schmidt RM, Pilmann Laursen R, Bruun S, et al. "Probiotics in late infancy reduce the incidence of eczema: A 
randomized controlled trial." Pediatr Allergy Immunol. 2019;00:1â€“6.156Leyer, G.J., S. Li, M.E. Mubasher, C. Reifer, and A.C. Ouwehand."Probiotic effects on cold and influenza-like symptom 
incidence and duration in children." Pediatrics 124.2 (2009): e172-e179.
157Alamoudi, Najlaa M et al.: "Effect of Probiotic Lactobacillus reuteri on Salivary Cariogenic Bacterial Counts among 
Groups of Preschool Children in Jeddah, Saudi Arabia: A Randomized Clinical Trial." The Journal of clinical pediatric 
dentistry vol. 42,5 (2018): 331-338. doi:10.17796/1053-4625-42.5.2
158Cannon, Mark et al.: "Effectiveness of CRT at measuring the salivary level of bacteria in caries prone children 
with probiotic therapy." The Journal of clinical pediatric dentistry vol. 38,1 (2013): 55-60. doi:10.17796/
jcpd.38.1.b481624264142082
159Maya-Barrios, A et al.: "Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of 
pharyngitis/tonsillitis in children: randomised controlled trial." Beneficial microbes vol. 12,2 (2021): 137-145. doi:10.3920/
BM2020.0171
160Navarro-LÃ³pez, Vicente et al. "Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use 
of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial." JAMA dermatology 
vol. 154,1 (2018): 37-43.
161Tan-Lim, Carol Stephanie C et al. "Comparative effectiveness of probiotic strains for the treatment of pediatric atopic 
dermatitis: A systematic review and network meta-analysis." Pediatric allergy and immunology : official publication of 
the European Society of Pediatric Allergy and Immunology, 10.1111/pai.13305. 10 Jun. 2020, doi:10.1111/pai.13305
162Taipale, T., K. PienihÃ¤kkinen, E. Isolauri, C. Larsen, E. Brockmann, P. Alanen, J. Jokela, and E. SÃ¶derling. "Bifidobacterium 
animalis subsp. lactis BB-12 in reducing the risk of infections in infancy." British Journal of Nutrition 105.3 (2011): 409-
416.
163Nocerino et al. "The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BBâ€12Â® in infant colic: A randomised, 
double blind, placeboâ€controlled trial" Aliment Pharmacol Ther. 2019;00:1â€“11.
164Cazzola, Mario et al.: "Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: 
a randomized, double-blind, placebo-controlled pilot study." Therapeutic advances in respiratory disease vol. 4,5 
(2010): 271-8. doi:10.1177/1753465810379010
165Langkamp-Henken, Bobbi et al.: "Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a 
lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-
controlled study." The British journal of nutrition vol. 113,3 (2015): 426-34. doi:10.1017/S0007114514003997
166Dubey, A.P., R. Krishnan, A. Chakravarti, A. Aggarwal, B.K. Atal, C. De Simone, V. Pandey, and A.R. Sahu.  "W1772 Use of 
Vsl# 3Â®(a New High Concentration Probiotic Mixture) in the Treatment of Childhood Diarrhea with Specific Reference 
to Rotavirus Diarrhea." Gastroenterology 134.4 (2008): A-712.
167Huynh, H.Q., J. deBruyn, L. Guan, H. Diaz, M. Li, S. Girgis, J. Turner, R. Fedorak, and K. Madsen. "Probiotic preparation 
VSL# 3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study." Inflammatory bowel 
diseases 15.5 (2009): 760-768.
168Miele, E., F. Pascarella, E. Giannetti, L. Quaglietta, R.N. Baldassano, and A. Staiano. "Effect of a Probiotic Preparation 
(VSL# 3) on induction and maintenance of Remission in children with ulcerative colitis." The American journal of 
gastroenterology 104.2 (2009): 437-443.
169Guandalini, S., G. Magazzu, A. Chiaro, V. La Balestra, G. Di Nardo, S. Gopalan, A. Sibal, C. Romano, R.B. Canani, 
P. Lionetti, and M. Setty.  "VSL# 3 improves symptoms in children with irritable bowel syndrome: a multicenter, 
randomized, placebo-controlled, double-blind, crossover study." Journal of pediatric gastroenterology and nutrition 51.1 
(2010): 24-30.
170Alisi A., G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, and V. Nobili. "Randomised 
Clinical Trial: The Beneficial Effects of VSL#3 in Obese Children with Non-alcoholic Steatohepatitis." Alimentary 
Pharmacology & Therapeutics 39.11 (2014): 1276-285.
171Anukam, K., E. Osazuwa, I. Ahonkhai, M. Ngwu, G. Osemene, A.W. Bruce, and G. Reid. "Augmentation of antimicrobial 
metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri 
RC-14: randomized, double-blind, placebo controlled trial." Microbes and Infection 8.6 (2006): 1450-1454.
172Reid, G., D. Charbonneau, J. Erb, B. Kochanowski, D. Beuerman, R. Poehner, and A.W. Bruce. "Oral use of Lactobacillus 
rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 
healthy women." FEMS Immunology & Medical Microbiology 35.2 (2003): 131-134.
173Anukam, K.C., E. Osazuwa, G.I. Osemene, F. Ehigiagbe, A.W. Bruce, and G. Reid. "Clinical study comparing probiotic 
Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis." Microbes and 
Infection 8.12 (2006): 2772-2776.
174Hummelen, R., J. Changalucha, N.L. Butamanya, A. Cook, J.D.F. Habbema, and G. Reid."Lactobacillus rhamnosus GR-1 
and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV." International Journal of Gynecology 
& Obstetrics 111.3 (2010): 245-248.
175Reid, G., A.W. Bruce, N. Fraser, C. Heinemann, J. Owen, and B. Henning. "Oral probiotics can resolve urogenital 
infections." FEMS Immunology & Medical Microbiology 30.1 (2001): 49-52.
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023176Martinez, R.C., S. A. Franceschini, M. C. Patta, S. M. Quintana, R. C. Candido, J. C. Ferreira, E. C. P. De Martinis, and G. 
Reid. "Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GRâ€1 and 
Lactobacillus reuteri RCâ€14." Letters in applied microbiology 48.3 (2009): 269-274.
177Martinez, R.C., S.A. Franceschini, M.C. Patta, S.M. Quintana, B.C. Gomes, E.C. De Martinis, and G. Reid.  "Improved cure 
of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: 
a randomized, double-blind, placebo-controlled trial." Canadian journal of microbiology 55.2 (2009): 133-138.
178Vujic, G., A.J. Knez, V.D. Stefanovic, and V.K. Vrbanovic. "Efficacy of orally applied probiotic capsules for bacterial 
vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study." European Journal of 
Obstetrics & Gynecology and Reproductive Biology 168.1 (2013): 75-79.
179Ya, W., C. Reifer, and L.E. Miller. "Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, 
randomized, placebo-controlled study." American journal of obstetrics and gynecology 203.2 (2010): 120-e1.
180Kern, A. M., J. M. Bohbot, and J. M. Cardot. "Preventive treatment of vulvovaginal candidosis with vaginal probiotic 
(gynophilusÂ®-lcr regeneransÂ®): Results of the observational study candiflore." La Lettre du Gynecologue 370 (2012): 
33-7.
181Marcone, V., G. Rocca, M. Lichtner, and E. Calzolari.  "Long-term vaginal administration of Lactobacillus rhamnosus as a 
complementary approach to management of bacterial vaginosis." International Journal of Gynecology & Obstetrics 110.3 
(2010): 223-226.
182Petricevic, L., and A. Witt. "The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after 
antibiotic treatment of bacterial vaginosis." BJOG: An International Journal of Obstetrics & Gynaecology 115.11 (2008): 
1369-1374.
183Rossi, A., T. Rossi, M. Bertini, and G. Caccia. "The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. 
Evaluation of clinical efficacy in a population of 40 women treated for 24 months." Archives of gynecology and 
obstetrics 281.6 (2010): 1065-1069.
184Agrawal, A., Lesley A. Houghton, J. Morris, B. Reilly, D. Guyonnet, N. Goupil Feuillerat, A. Schlumberger, S. Jakob, 
and P. J. Whorwell.  "Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DNâ€173 
010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation." Alimentary 
pharmacology & therapeutics 29.1 (2009): 104-114.
185Guyonnet, D., O. Chassany, P. Ducrotte, C. Picard, M. Mouret, Câ€H. Mercier, and C. Matuchansky. "Effect of a fermented 
milk containing Bifidobacterium animalis DNâ€173 010 on the healthâ€related quality of life and symptoms in irritable bowel 
syndrome in adults in primary care: a multicentre, randomized, doubleâ€blind, controlled trial." Alimentary pharmacology & 
therapeutics 26.3 (2007): 475-486.
186Yang, Y.X., M. He, G. Hu, J. Wei, P. Pages, X.H. Yang, and S. Bourdu-Naturel. "Effect of a fermented milk containing 
Bifidobacterium lactis DN-173010 on Chinese constipated women." World J Gastroenterol 14.40 (2008): 6237-6243.
187Pedone, C.A., A.O. Bernabeu, E.R. Postaire, C.F. Bouley, and P. Reinert.  "The effect of supplementation with 
milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care 
centres." International journal of clinical practice 53.3 (1998): 179-184.
188Pedone, C.A., C.C. Arnaud, E.R. Postaire, C.F. Bouley, and P. Reinert.  "Multicentric study of the effect of milk fermented 
by Lactobacillus casei on the incidence of diarrhoea." International journal of clinical practice 54.9 (2000): 568-571.
189SÃ½kora, J., K. ValeckovÃ¡, J. AmlerovÃ¡, K. Siala, P. Dedek, S. Watkins, J. VarvarovskÃ¡, F. StoÅ¾ickÃ½, P. Pazdiora, and J. 
Schwarz. "Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 
001 and the eradication of H. pylori in children: a prospective randomized double-blind study." Journal of clinical 
gastroenterology 39.8 (2005): 692-698.
190Lin, J.S., Y.H. Chiu, N.T. Lin, C.H. Chu, K.C. Huang, K.W. Liao, and K.C. Peng. "Different effects of probiotic species/strains 
on infections in preschool children: a double-blind, randomized, controlled study." Vaccine 27.7 (2009): 1073-1079.
191Hickson, M., A.L. D'Souza, N. Muthu, T.R. Rogers, S. Want, C. Rajkumar, and C.J. Bulpitt. "Use of probiotic Lactobacillus 
preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled 
trial." Bmj 335.7610 (2007): 80.
192Giovannini, M., C. Agostoni, E. Riva, F. Salvini, A. Ruscitto, G.V. Zuccotti, and G. Radaelli. "A randomized prospective 
double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in 
pre-school children with allergic asthma and/or rhinitis." Pediatric research 62.2 (2007): 215-220.
193Merenstein, D., M. Murphy, A. Fokar, R.K. Hernandez, H. Park, H. Nsouli, M.E. Sanders, B.A. Davis, V. Niborski, F. Tondu, 
and N.M. Shara. "Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the 
rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical 
trial." European journal of clinical nutrition 64.7 (2010): 669-677.
194Boge, T., M. RÃ©migy, S. Vaudaine, J. Tanguy, R. Bourdet-Sicard, and S. Van Der Werf. "A probiotic fermented dairy drink 
improves antibody response to influenza vaccination in the elderly in two randomised controlled trials." Vaccine 27.41 
(2009): 5677-5684.
195Guillemard, E., F. Tondu, F. Lacoin, and J. Schrezenmeir. "Consumption of a fermented dairy product containing the 
probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised 
controlled trial." British journal of nutrition 103.01 (2010): 58-68.196Guillemard, E., J. Tanguy, A.L. Flavigny, S. de la Motte, and J. Schrezenmeir. "Effects of consumption of a fermented dairy 
product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections 
in shift workers in a randomized controlled trial." Journal of the American College of Nutrition 29.5 (2010): 455-468.
197Marcos, A., J. W., E. Nova, S. GÃ³mez, A. Alvarez, R. Alvarez, J.A. Mateos, and J.M. Cobo. "The effect of milk fermented by 
yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination 
stress." European journal of nutrition 43.6 (2004): 381-389.
198Meyer, A.L., M. Micksche, I. Herbacek, and I. Elmadfa.  "Daily intake of probiotic as well as conventional yogurt has 
a stimulating effect on cellular immunity in young healthy women." Annals of nutrition and metabolism 50.3 (2006): 
282-289.
199Ortiz-Andrellucchi, A., A. SÃ¡nchez-Villegas, C. RodrÃ­guez-Gallego, A. Lemes, T. Molero, A. Soria, L. Pena-Quintana, 
M. Santana, O. RamÃ­rez, J. GarcÃ­a, and F. Cabrera. "Immunomodulatory effects of the intake of fermented milk with 
Lactobacillus casei DN114001 in lactating mothers and their children." British journal of nutrition 100.04 (2008): 834-845.
200Tiollier, E., M. Chennaoui, D. Gomez-Merino, C. Drogou, E. Filaire, and C.Y. Guezennec. "Effect of a probiotics 
supplementation on respiratory infections and immune and hormonal parameters during intense military 
training." Military medicine 172.9 (2007): 1006-1011.
201Turchet, P., M. Laurenzano, S. Auboiron, and J. M. Antoine. "Effect of fermented milk containing the probiotic 
Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot 
study." The journal of nutrition, health & aging 7.2 (2002): 75-77.
202Alberda C., S. Marcushamer, T. Hewer, N. Journault and D. Kutsogiannis "Feasibility of a Lactobacillus casei Drink in 
the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile." Nutrients. 2018 May; 
10(5):539
203Saavedra, J.M., A. Abi-Hanna, N. Moore, and R.H. Yolken.  "Long-term consumption of infant formulas containing live 
probiotic bacteria: tolerance and safety." The American journal of clinical nutrition 79.2 (2004): 261-267.
204CorrÃªa, N.B., L.A. PÃ©ret Filho, F.J. Penna, F.M.S. Lima, and J.R. Nicoli.  "A randomized formula controlled trial 
of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in 
infants." Journal of clinical gastroenterology 39.5 (2005): 385-389.
205Baldassarre M.E., Laforgia N., Fanelli M., Laneve A., Grosso R., and Lifschitz C. "Lactobacillus GG Improves Recovery in 
Infants with Blood in the Stools and Presumptive Allergic Colitis Compared with Extensively Hydrolyzed Formula Alone." 
The Journal of Pediatrics 156.3 (2010): 397-401.
206Canani R.B., Nocerino R., Terrin G., Frediani T., Lucarelli S., Cosenza L., Passariello A., Leone L., Granata V., Di Costanzo 
M., Pezzella V., and Troncone R. "Formula Selection for Management of Children with Cow's Milk Allergy Influences the 
Rate of Acquisition of Tolerance: A Prospective Multicenter Study." The Journal of Pediatrics 163.3 (2013)
207Canani R.B., Di Costanzo M., Bedogni G., Amoroso A., Cosenza L., Di Scala C., Granata V., and Nocerino R. "Extensively 
Hydrolyzed Casein Formula Containing Lactobacillus Rhamnosus GG Reduces the Occurrence of Other Allergic 
Manifestations in Children with Cow's Milk Allergy: 3-year Randomized Controlled Trial." Journal of Allergy and Clinical 
Immunology 139.6 (2017)
208Nocerino, Rita et al.: "The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the 
Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study." The Journal of pediatrics vol. 232 (2021): 
183-191.e3. doi:10.1016/j.jpeds.2021.01.059
209Koebnick, C., Wagner, I., Leitzmann, P., Stern, U., and Zunft, H. (2003). Probiotic beverage containing Lactobacillus casei 
Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 17, 655-659.
210Tilley, L., Keppens, K., Kushiro, A., Takada, T., Sakai, T., Vaneechoutte, M., and Degeest, B. (2014). A probiotic fermented 
milk drink containing Lactobacillus casei strain Shirota improves stool consistency of subjects with hard stools. 
International Journal Of Probiotics And Prebiotics 9, 23-30.
211Dong, H., Rowland, I., Thomas, L., and Yaqoob, P. (2013). Immunomodulatory effects of a probiotic drink containing 
Lactobacillus casei Shirota in healthy older volunteers. European Journal Of Nutrition 52, 1853-1863.
212Gleeson, M., Bishop, N., Oliveira, M., and Tauler, P. (2011). Daily probioticâ€™s (Lactobacillus casei Shirota) reduction of 
infection incidence in athletes. International Journal Of Sport Nutrition And Exercise Metabolism 21, 55-64.
213Ivory, K., Chambers, S., Pin, C., Prieto, E., ArquÃ©s, J., and Nicoletti, C. (2008). Oral delivery of Lactobacillus casei Shirota 
modifies allergen-induced immune responses in allergic rhinitis. Clinical & Experimental Allergy 38, 1282-1289.
214Nagao, F., Nakayama, M., Muto, T., and Okumura, K. (2000). Effects of a Fermented Milk Drink Containing Lactobacillus 
casei Strain Shirota on the Immune System in Healthy Human Subjects. Bioscience, Biotechnology And Biochemistry 
64, 2706-2708.
215Rao A.V., Bested A.C, Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., and Logan A.C. "A Randomized, Double-blind, 
Placebo-controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome." Gut Pathogens 1.1 
(2009): 6.
216Kato-Kataoka A., Nishida K., Takada M., Suda K., Kawai M., Shimizu K., Kushiro A., Hoshi R., Watanabe O., Igarashi T., 
Miyazaki K., Kuwano Y., and Rokutan K. "Fermented Milk Containing Lactobacillus Casei Strain Shirota Prevents the 
Onset of Physical Symptoms in Medical Students under Academic Examination Stress." Beneficial Microbes 7.2 (2016): 
153-56.
Clinical Guide to Probiotic Products Available in Canada 15th Edition 2023This Clinical Guide is available online at www.ProbioticChart.ca
For inquiries related to the content, please contact author Dragana Skokovic-Sunjic DSunjic@bhsoftinc.com
For ordering additional copies of this Clinical Guide contact info@bhsoftinc.comThe Clinical Guide to Probiotic Products Available in Canada is made possible 
through an unrestricted education grant from the Alliance for Education on 
Probiotic Products.  
Product inclusion in The Clinical Guide to Probiotic Products Available in 
Canada is based on scientific evidence and is not influenced by or limited to 
members of AEProbio.
Alliance Members Canada
Alliance Members USA
22
Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S and other countries. App Store is a service mark of Apple Inc. Google Play is a trademark of Google Inc.AEProbio (the Alliance for Education on Probiotics) is 
dedicated to establishing probiotics as front-line therapy 
for the protection, restoration, and enhancement of human 
health. Every year, we provide an unbiased review and 
summary of the available scientific evidence on the efficacy 
of specific probiotic products.
www.AEProbio.comGet the Probiotic Guide App: 
Your trusted resource for selecting 
probiotics. 
Visit the Probiotic Guide Website 